RNXT · Renovorx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0K | - | $266.0K | $422.0K | $197.0K | - | - | - | - | - |
| Cost of Revenue | $84.0K | - | $53.0K | $152.0K | $94.0K | - | - | - | - | - |
| Gross Profit | $479.0K | - | $213.0K | $270.0K | $103.0K | - | - | - | - | - |
| R&D | $1.23M | - | $1.69M | $1.43M | $1.64M | - | $1.65M | $1.54M | $1.26M | - |
| SG&A | $2.72M | - | $1.18M | $1.52M | $1.22M | - | $1.18M | $1.49M | $1.22M | - |
| Total Operating Expenses | $3.95M | - | $3.41M | $2.95M | $3.21M | - | $2.83M | $3.03M | $2.48M | - |
| D&A | $1.0K | - | $1.00M | $1.00M | $1.0K | - | - | - | - | - |
| Operating Income | ($3.47M) | - | ($3.20M) | ($2.68M) | ($3.11M) | - | ($2.83M) | ($3.03M) | ($2.48M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | - | - |
| Net Income | ($3.52M) | - | ($2.91M) | ($2.90M) | ($2.42M) | - | ($2.47M) | ($2.39M) | ($1.08M) | - |
| EPS - Basic | ($0.09) | - | ($0.08) | ($0.08) | ($0.08) | - | ($0.10) | ($0.10) | ($0.07) | - |
| EPS - Diluted | ($0.09) | - | ($0.08) | ($0.08) | ($0.08) | - | ($0.10) | ($0.10) | ($0.07) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.36M | $7.02M | $10.04M | $12.31M | $14.58M | $7.15M | $9.56M | $11.74M | $4.39M | $1.17M |
| Accounts Receivable | $280.0K | $139.0K | $169.0K | $363.0K | $242.0K | $43.0K | - | - | - | - |
| Inventory | $379.0K | $189.0K | $272.0K | - | - | $0 | - | - | - | - |
| Accounts Payable | $1.12M | $799.0K | $869.0K | $671.0K | $967.0K | $586.0K | $686.0K | $438.0K | $356.0K | $561.0K |
| Current Assets | $13.72M | $7.89M | $10.98M | $13.39M | $15.74M | $7.83M | - | - | - | $1.47M |
| Total Assets | $13.96M | $8.10M | $11.21M | $13.64M | $16.01M | $8.12M | $10.03M | $12.00M | $4.79M | $1.47M |
| Current Liabilities | $1.92M | $1.96M | $1.88M | $1.56M | $1.74M | $1.91M | $1.77M | $1.31M | $1.09M | $1.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.70M | $2.67M | $3.13M | $3.00M | $2.86M | $3.64M | $2.96M | $2.73M | $3.02M | $4.47M |
| Stockholders' Equity | $11.27M | $5.42M | $8.08M | $10.64M | $13.16M | $4.48M | $7.07M | $9.27M | $1.77M | ($3.00M) |
| Retained Earnings | ($64.91M) | ($61.39M) | ($58.45M) | ($55.53M) | ($52.64M) | ($50.22M) | ($47.34M) | ($44.87M) | ($42.48M) | ($41.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.71M) | - | - | - | ($3.38M) | - | - | - | ($2.20M) | - |
| Investing Cash Flow | $0 | - | - | - | ($2.0K) | - | - | - | - | - |
| Financing Cash Flow | $9.05M | - | - | - | $10.81M | - | - | - | $5.42M | - |
| CapEx | $0 | - | - | - | $2.0K | - | - | - | - | - |
| Free Cash Flow | ($3.71M) | - | - | - | ($3.38M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 85.1% | - | 80.1% | 64.0% | 52.3% | - | - | - | - | - |
| Operating margin | -616.2% | - | -1203.0% | -634.6% | -1578.7% | - | - | - | - | - |
| EBITDA margin | -616.0% | - | -827.1% | -397.6% | -1578.2% | - | - | - | - | - |
| Net margin | -625.4% | - | -1094.7% | -686.0% | -1228.4% | - | - | - | - | - |
| Free cash flow margin | -658.8% | - | - | - | -1717.3% | - | - | - | - | - |
| FCF / Net income | 1.05 | - | - | - | 1.40 | - | - | - | - | - |
| R&D / Revenue | 218.1% | - | 633.5% | 337.9% | 833.5% | - | - | - | - | - |
| SG&A / Revenue | 483.1% | - | 442.9% | 360.7% | 618.8% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.2% | - | -26.0% | -21.2% | -15.1% | - | -24.6% | -19.9% | -22.5% | - |
| Return on equity | -31.3% | - | -36.0% | -27.2% | -18.4% | - | -34.9% | -25.8% | -60.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.15 | 4.02 | 5.83 | 8.61 | 9.07 | 4.10 | - | - | - | 1.25 |
| Quick ratio | 6.95 | 3.93 | 5.68 | 8.61 | 9.07 | 4.10 | - | - | - | 1.25 |
| Cash ratio | 6.44 | 3.58 | 5.33 | 7.91 | 8.40 | 3.75 | 5.40 | 8.96 | 4.02 | 1.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.24 | 1.49 | 1.39 | 1.28 | 1.22 | 1.81 | 1.42 | 1.29 | 2.71 | -0.49 |
| Liabilities / Assets | 0.19 | 0.33 | 0.28 | 0.22 | 0.18 | 0.45 | 0.30 | 0.23 | 0.63 | 3.05 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.02 | 0.03 | 0.01 | - | - | - | - | - |
| Inventory turnover | 0.22 | - | 0.19 | - | - | - | - | - | - | - |
| Days sales outstanding | 182d | - | 232d | 314d | 448d | - | - | - | - | - |
| Days inventory outstanding | 1647d | - | 1873d | - | - | - | - | - | - | - |
| Days payable outstanding | 4862d | - | 5985d | 1611d | 3755d | - | - | - | - | - |
| Cash conversion cycle | -3034d | - | -3880d | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.4x | - | 5.8x | 4.5x | 2.4x | - | 3.7x | 2.9x | 11.3x | - |
| P / S | 68.2x | - | 175.0x | 114.0x | 157.8x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 185.8% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 365.0% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.5% | - | -13.2% | 11.7% | -25.6% | - | 5.2% | 10.1% | 24.1% | - |
| Net income growth (YoY) | -45.5% | - | -17.8% | -21.2% | -124.9% | - | -73.9% | -2.7% | 67.0% | - |
| EPS growth (YoY) | -12.5% | - | 20.0% | 20.0% | -14.3% | - | 58.3% | 54.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -9.6% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -14.4% | 21.1% | 14.2% | 14.8% | 644.6% | - | 117750.0% | 680.5% | -45.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.12M totalAll Other Segments$1.12M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing RenovoRx against the 5 most active filers in the same SIC group.